USPTO Art Unit 1678 Prosecution Statistics

Art Unit Information

Art Unit: 1678
Group: 1670
Tech Center: 1600
Total Cases: 4,285
Last Active: July 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19279954SYSTEMS, METHODS AND COMPOSITIONS FOR ANALYSIS OF PROTEOFORMSJuly 2025March 2026Allow711NoNo
19199750METHODS AND DEVICES FROM ISOLATION OF TUMOR CELLSMay 2025January 2026Allow911YesNo
19171004METHODS FOR PERFORMING MINIATURIZED DYNAMIC ASSAYS USING MICROFLUIDICS AND RELATED SYSTEMSApril 2025February 2026Allow1011NoNo
19084523A COMPOSITION COMPRISING AFLIBERCEPT AND A VARIANT THEREOF, AND RELATED METHODS AND USESMarch 2025October 2025Allow700YesNo
19073950METHODS OF ASSAYING PHOSPHORYLATED TAU PROTEIN IN A SAMPLEMarch 2025December 2025Allow920YesNo
19038526SYSTEMS AND METHODS FOR MEASURING CHANGES IN CELLULAR ACTIVITY IN LIVE TISSUEJanuary 2025July 2025Allow611YesNo
19023243NANO FLUORESCENT LATEX PIGMENT WITH HIGH FLUORESCENCE INTENSITY AND HIGH STABILITY AND PREPARATION METHOD THEREFORJanuary 2025October 2025Allow911NoNo
18953525RECOMBINANT AMEBOCYTE CLOTTING FACTORS AND USES THEREOFNovember 2024September 2025Allow1011YesNo
18934708METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMSNovember 2024July 2025Allow911YesNo
18923470BIOMOLECULE DETECTION METHOD USING DIFFUSION ORDERED SPECTROSCOPYOctober 2024April 2025Allow510YesNo
18918272INDICATOR-BASED ANALYSIS OF A SAMPLEOctober 2024September 2025Allow1111NoNo
18789799RAPID DETECTION METHOD FOR RICIN TOXINJuly 2024December 2024Allow510YesNo
18769708ASSAY METHOD OF ANTIBODYJuly 2024March 2025Allow810NoNo
18761492DIRECT DETECTION OF SINGLE MOLECULES ON MICROPARTICLESJuly 2024September 2025Allow1411NoNo
18752739METHOD FOR DETECTING AFLATOXIN B1 CONTENT USING FLUORESCENCE ANALYSIS BASED ON OPTICAL SECTIONINGJune 2024September 2024Allow200YesNo
18722997MAGNETIC CHEMILUMINESCENCE IMMUNOASSAY KIT BASED ON BIFUNCTIONAL FUSION PROTEIN FOR MYCOTOXINS, AND USE THEREOFJune 2024March 2025Allow911YesNo
18679192COMPOSITION COMPRISING AFLIBERCEPT AND A VARIANT THEREOF, AND RELATED METHODS AND USESMay 2024November 2024Allow501YesNo
18677547IMMUNE CELLS HAVING CO-EXPRESSED SHRNAS AND LOGIC GATE SYSTEMSMay 2024August 2025Abandon1501NoNo
18676285Anti-Bed Bug Monoclonal Antibodies and Methods of Making and Uses ThereofMay 2024November 2025Abandon1801NoNo
18674179Bead-based analysis of a sampleMay 2024January 2025Allow810YesNo
18661576TUBERCULOSIS DETECTION KITMay 2024January 2025Allow820YesNo
18648822SYSTEM AND METHOD FOR DETECTING, ENUMERATING, OR EXTRACTING MICROORGANISMS IN A SAMPLEApril 2024September 2025Allow1721YesNo
18643947ENHANCED DETECTION AND QUANTITATION OF BIOMOLECULESApril 2024October 2025Allow1820YesNo
18642104ULTRA-SENSITIVE DETECTION OF MOLECULES OR PARTICLES USING BEADS OR OTHER CAPTURE OBJECTSApril 2024September 2024Allow501NoNo
18640086METHODS OF DIAGNOSING OR TREATING LYME DISEASEApril 2024October 2025Allow1831YesNo
18628482COMPOSITIONS AND METHODS TO DETECT GASTROINTESTINAL DISEASEApril 2024July 2025Abandon1510NoNo
18621418Means and Methods for the Determination of the Biological Activity of Neurotoxin Polypeptides in CellsMarch 2024February 2025Allow1100YesNo
18616550DETECTION OF ANTI-p53 ANTIBODIESMarch 2024January 2025Allow1010NoNo
18611482METHODS AND DEVICES FOR ANALYZING SPECIES TO DETERMINE DISEASESMarch 2024December 2025Abandon2111NoNo
18609023Methods and Compositions for Modulating Beta Chain Mediated ImmunityMarch 2024July 2025Allow1611NoNo
18607753Composition and MethodMarch 2024October 2025Abandon1920NoNo
18599665BIOMARKERS AND METHODS FOR ASSESSING MYOCARDIAL INFARCTION AND SERIOUS INFECTION RISK IN RHEUMATOID ARTHRITIS PATIENTSMarch 2024October 2025Abandon2020NoNo
18597358METHODS FOR CONDUCTING MULTIPLEXED ASSAYSMarch 2024July 2025Allow1610NoNo
18595584BIODOSIMETRY PANELS AND METHODSMarch 2024February 2026Allow2312YesNo
18587846Antigens Derived from Citrullinated 14-3-3 and Uses Thereof in the Diagnosis of Rheumatoid ArthritisFebruary 2024November 2025Abandon2111NoNo
18586286COMPARTMENTALIZED ASSAYS OF BISPECIFIC AND MULTISPECIFIC BIOLOGICSFebruary 2024August 2025Allow1811YesNo
18585679METHOD OF DETERMINING AN IMMUNOGENIC RESPONSE CHARACTERISTIC OF A CHEMICAL SUBSTANCEFebruary 2024March 2025Allow1320YesNo
18585578Methods for Screening B Cell LymphocytesFebruary 2024December 2025Abandon2220NoNo
18438790MATERIALS AND METHODS FOR ISOLATING SELF-ANTIGEN POLYPEPTIDESFebruary 2024December 2025Allow2231YesNo
18437439NON-INVASIVE CANCER DETECTION AND ANALYSIS BY SINGLE-MOLECULE IMAGINGFebruary 2024March 2025Allow1400NoNo
18438105SPACING LINKER GROUP DESIGN FOR BRIGHTNESS ENHANCEMENT IN DIMERIC OR POLYMERIC DYESFebruary 2024July 2025Allow1721YesNo
18436594ULTRA BRIGHT DIMERIC OR POLYMERIC DYES WITH SPACING LINKER GROUPSFebruary 2024April 2025Allow1420YesNo
18434947LATERAL FLOW TESTINGFebruary 2024May 2025Allow1511NoNo
18432995MARKERS FOR RENAL DISEASEFebruary 2024November 2024Allow910YesNo
18428535ASSAYS FOR DETECTING THE PRESENCE OR AMOUNT OF AN ANTI-DRUG ANTIBODYJanuary 2024October 2025Allow2130NoNo
18427264ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIESJanuary 2024August 2025Abandon1810NoNo
18420588ANTIGEN-BINDING MOLECULES THAT BIND CD38 AND/OR CD28, AND USES THEREOFJanuary 2024December 2025Allow2320NoNo
18417845SELECTIVE OPTICAL DETECTION OF ORGANIC ANALYTES IN LIQUIDSJanuary 2024October 2025Allow2110NoNo
18415933OLIGOPEPTIDEJanuary 2024November 2025Allow2210YesNo
18414438Compositions and Methods for Identifying and Modulating Metabolic HealthJanuary 2024June 2025Abandon1701NoNo
18414339KITS AND METHODS TO DISTINGUISH FALSE LABOR AND TRUE LABORJanuary 2024December 2024Allow1120NoNo
18412596METHOD FOR ACCURATE DIAGNOSIS OF A DISEASE TARGETING BIOMARKERS IN LIQUID BIOPSYJanuary 2024January 2025Allow1310YesNo
18410096VALIDATION OF NATURAL MATRICES FOR THERAPEUTIC USEJanuary 2024October 2025Allow2131YesNo
18406399METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUSJanuary 2024April 2025Allow1520YesNo
18405536Bed Bugs Detection DeviceJanuary 2024August 2024Allow700YesNo
18401919REPORTER PROTEIN FUSED ANTIBODIESJanuary 2024June 2025Abandon1701NoNo
18392925IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYSDecember 2023April 2025Abandon1510NoNo
18544491METHOD FOR STABILIZING EXTRACELLULAR VESICLESDecember 2023March 2025Allow1511YesNo
18533851DYNAMIC TRACKING OF CAPTURED TARGETS FOR ENHANCED DIGITAL BIOSENSINGDecember 2023July 2025Allow1910NoNo
18526139THERAPEUTIC PROTEIN SELECTION IN SIMULATED IN VIVO CONDITIONSDecember 2023May 2025Abandon1711NoNo
18523208PLASMA THERMOGRAMS FOR DIAGNOSIS AND TREATMENT OF ACUTE MYOCARDIAL INFARCTIONNovember 2023August 2025Allow2021NoNo
18519724MULTI-SPECTRAL MICROPARTICLE-FLUORESCENCE PHOTON CYTOMETRYNovember 2023December 2025Allow2411NoNo
18514615BIOANALYTICAL ANALYSIS OF SITE-SPECIFIC ANTIBODY DRUG CONJUGATESNovember 2023February 2025Abandon1510NoNo
18512759Anti-CCR8 Antibodies and Uses ThereofNovember 2023August 2025Allow2111NoNo
18504971IMMUNOASSAY TEST DEVICE WITH TWO FLUID FLOW PATHS FOR DETECTION AND DIFFERENTIATION OF TWO OR MORE ANALYTESNovember 2023December 2025Allow2520NoNo
18500149REAGENT FOR MASS SPECTROMETRYNovember 2023January 2026Allow2701YesNo
18491255DETECTION OF MOLECULAR ASSOCIATIONSOctober 2023November 2025Allow2511YesNo
18489398BIOSENSOR MICROARRAY COMPOSITIONS AND METHODSOctober 2023February 2026Allow2820NoNo
18487900HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCEROctober 2023August 2025Abandon2211NoNo
18486086ANTIBODIES TO TIGITOctober 2023May 2025Allow1911YesNo
184855751,1 '-[[(SUBSTITUTED ALKYL)IMINO]BIS(ALKYLENE)]BIS-FERROCENES AND THEIR USE IN ELECTROCHEMICAL ASSAYS BY LABELLING SUBSTRATES OF INTERESTOctober 2023June 2024Allow800YesNo
18482286KITS AND METHODS FOR PREDICTION AND TREATMENT OF PREECLAMPSIAOctober 2023November 2024Allow1410YesNo
18375755METHOD FOR GENERATING HIGH AFFINITY ANTIBODIESOctober 2023July 2025Allow2210NoNo
18479246PREVENTION AND/OR TREATMENT OF INFLAMMATORY SKIN DISEASEOctober 2023November 2025Abandon2611NoNo
18473464KINETIC IMMUNOASSAY SYSTEMS AND METHODSSeptember 2023October 2025Allow2411YesNo
18467302ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ANDRENDOMEDULLINSeptember 2023November 2024Allow1410YesNo
18367986HEALTH TEST FOR A BROAD SPECTRUM OF HEALTH PROBLEMSSeptember 2023March 2025Allow1820YesNo
18367823METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUSSeptember 2023October 2023Allow110NoNo
18242804Highly Sensitive System and Method for Analysis of TroponinSeptember 2023June 2025Allow2210NoNo
18243045SYSTEMS AND METHODS FOR TESTING AND SCREENING USING COMPOUND BOUND SUBSTRATESSeptember 2023November 2024Allow1521YesNo
18460944IL-7 Binding Proteins and Their Use in Medical TherapySeptember 2023May 2024Allow900NoNo
18459908METHODS FOR ASSESSING MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE PATIENTSSeptember 2023May 2025Allow2130YesNo
18240178DEVICES AND METHODS FOR BODILY FLUID COLLECTION AND DISTRIBUTIONAugust 2023July 2025Allow2220NoNo
18454975METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE POREAugust 2023August 2025Abandon2421YesNo
18453745TARGET-BINDING ACTIVATED SPLIT REPORTER SYSTEMS FOR ANALYTE DETECTION AND RELATED COMPONENTS AND METHODSAugust 2023November 2024Allow1510NoNo
18452504METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERSAugust 2023June 2025Allow2241YesNo
18449936COMPOUNDS AND THEIR USE IN ANALYTICAL METHODSAugust 2023December 2025Allow2821NoNo
18446969USE OF AN INTEGRATED MICROFLUIDIC CHIP FOR ANALYSIS OF CELL MOTILITY AND PREDICTION AND PROGNOSIS OF PATIENT SURVIVALAugust 2023August 2025Allow2420YesNo
18364392SUBSTANCE LABELING PATCH, METHOD AND APPARATUS FOR TISSUE DIAGNOSIS USING THE SAMEAugust 2023August 2024Allow1210YesNo
18263764FFN FLUORESCENCE RELEASE ASSAY (FFRA) AND METHODS OF USING SAMEAugust 2023March 2026Allow3100NoNo
18227421Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses ThereofJuly 2023August 2025Allow2530YesNo
18227151ELISA FOR DIAGNOSIS OF HAEMONCHUS LONGISTIPES INFECTION IN CAMELSJuly 2023February 2024Allow620YesNo
18227030ELISA FOR DIAGNOSIS OF HAEMONCHUS LONGISTIPES INFECTION IN CAMELSJuly 2023December 2023Allow520YesNo
18358884HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3July 2023February 2026Allow3121NoNo
18353683COMPOSITIONS AND METHODS FOR ASSAYING PLATELET REACTIVITY AND TREATMENT SELECTIONJuly 2023December 2024Allow1710YesNo
18222447Discovering Active Components in Herbals by Manipulating Common ElementsJuly 2023September 2025Abandon2620YesNo
18351796CONTACT-TYPE PATCH, STAINING METHOD USING THE SAME, AND MANUFACTURING METHOD THEREOFJuly 2023September 2024Allow1410YesNo
18350764SERUM METABOLIC BIOMARKERS FOR DETECTING TUBERCULOSIS AND TUBERCULOSIS DETECTION KITJuly 2023February 2025Allow1911YesNo
18349016NANOSTRUCTURES FOR IMPROVED MOLECULAR DETECTIONJuly 2023September 2025Abandon2621YesNo
18348201NUCLEIC ACID-TAGGED COMPOSITIONS AND METHODS FOR MULTIPLEXED PROTEIN-PROTEIN INTERACTION PROFILINGJuly 2023August 2024Allow1420YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1678.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
51
Examiner Affirmed
42
(82.4%)
Examiner Reversed
9
(17.6%)
Reversal Percentile
1.5%
Lower than average

What This Means

With a 17.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
343
Allowed After Appeal Filing
75
(21.9%)
Not Allowed After Appeal Filing
268
(78.1%)
Filing Benefit Percentile
9.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1678 - Prosecution Statistics Summary

Executive Summary

Art Unit 1678 is part of Group 1670 in Technology Center 1600. This art unit has examined 4,285 patent applications in our dataset, with an overall allowance rate of 64.2%. Applications typically reach final disposition in approximately 38 months.

Comparative Analysis

Art Unit 1678's allowance rate of 64.2% places it in the 21% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1678 receive an average of 2.16 office actions before reaching final disposition (in the 71% percentile). The median prosecution time is 38 months (in the 19% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.